Mark Joseph Tebbe | Researchain

Archive Network Publication Hotspot Collaboration

Network

Latest external collaboration on country level. Dive into details by clicking on the dots.

Explore More

Hotspot

Dive into the research topics where Mark Joseph Tebbe is active.

Explore More

Publication

Featured researches published by Mark Joseph Tebbe.

Journal of Medicinal Chemistry | 1997

Antirhino/Enteroviral Vinylacetylene Benzimidazoles: A Study of Their Activity and Oral Plasma Levels in Mice

Mark Joseph Tebbe; Wayne A. Spitzer; Frantz Victor; Shawn Christopher Miller; Chris C. Lee; Thomas R. Sattelberg; Emma R. McKinney; Joseph Tang

Archive | 1997

Anti-viral compound

Joseph M. Colacino; Beverly A. Heinz; Louis Nickolaus Jungheim; Shawn Christopher Miller; Wayne A. Spitzer; Joseph Tang; Mark Joseph Tebbe; Frantz Victor

Archive | 2003

Substituted arylcyclopropylacetamides as glucokinase activators

Andreas Gerhard Weichert; David Barrett; Stefan Heuser; Rainer Riedl; Mark Joseph Tebbe; Andrea Zaliani

Journal of Medicinal Chemistry | 2002

4-Substituted D-glutamic acid analogues: the first potent inhibitors of glutamate racemase (MurI) enzyme with antibacterial activity.

Alfonso De Dios; Lourdes Prieto; Jose Alfredo Martin; Almudena Rubio; Jesús Ezquerra; Mark Joseph Tebbe; Beatriz López de Uralde; Justina Martín; Ana Sánchez; Deborah L. LeTourneau; James Eugene Mcgee; Carole Boylan; Thomas R. Parr, Jr.,§,⊥ and; Michele Ceceil Smith

Bioorganic & Medicinal Chemistry Letters | 2004

Discovery of a novel bicycloproline P2 bearing peptidyl α-ketoamide LY514962 as HCV protease inhibitor

Yvonne Yip; Frantz Victor; Jason Lamar; Robert B. Johnson; Q.May Wang; Donna Barket; John Irvin Glass; Ling Jin; Lifei Liu; Daryl Venable; Mark Wakulchik; Congping Xie; Beverly A. Heinz; Elcira C. Villarreal; Joe Colacino; Nathan Yumibe; Mark Joseph Tebbe; John E. Munroe; Shu-Hui Chen

Archive | 2003

Pyrrole-2, 5-dione derivatives and their use as gsk-3 inhibitors

Pamela Ann Albaugh; Jochen Ammenn; Timothy Paul Burkholder; Joshua Ryan Clayton; Scott Eugene Conner; Brian Eugene Cunningham; Thomas A. Engler; Kelly Wayne Furness; James Robert Henry; Yihong Li; Sushant Malhotra; Mark Joseph Tebbe; Guoxin Zhu

Letters in Drug Design & Discovery | 2005

P1 and P1; Optimization of [3,4]-Bicycloproline P2 Incorporated Tetrapeptidyl α-Ketoamide Based HCV Protease Inhibitors

Shu-Hui Chen; Jason Lamar; Yvonne Yip; Frantz Victor; Robert B. Johnson; Q.May Wang; John Irvin Glass; Beverly A. Heinz; Joseph M. Colacino; Deqi Guo; Mark Joseph Tebbe; John E. Munroe

Journal of Pharmaceutical Sciences | 1999

Application of oral bioavailability surrogates in the design of orally active inhibitors of rhinovirus replication

Robert E. Stratford; Michael P. Clay; Beverly A. Heinz; Michael T. Kuhfeld; Stacy J. Osborne; Diane L. Phillips; Stephanie Ann Sweetana; Mark Joseph Tebbe; Vasu Vasudevan; Larry L. Zornes; Terry D. Lindstrom

Archive | 2003

Pyrrole-2, 5dione derivatives and their used as GSK-3 inhibitors

Pamela Ann Albaugh; Jochen Ammenn; Timothy Paul Burkholder; Joshua Ryan Clayton; Scott Eugene Conner; Brian Eugene Cunningham; Thomas A. Engler; Kelly Wayne Furness; James Robert Henry; Sushant Malhotra; Mark Joseph Tebbe; Guoxin Zhu; Yihong Li; Brian R. Berridge; Charles Edward Ruegg; John M. Sullivan

Archive | 1996